XM does not provide services to residents of the United States of America.
E
E

Ecolab


News

U.S. Booking Holdings, Doordash, Vertex Pharmaceuticals

U.S. RESEARCH ROUNDUP- Booking Holdings, Doordash, Vertex Pharmaceuticals Aug 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Booking Holdings, Doordash and Vertex Pharmaceuticals, on Monday. HIGHLIGHTS * Academy Sports and Outdoors Inc ASO.O : JP Morgan cuts to neutral from overweight * Booking Holdings Inc BKNG.O : Jefferies cuts target price to $4350 from $4650 * Doordash DASH.O : D.A.
A
B
C
C
C
C
E
V
E
A
B
C
C
C
C

U.S. Booking Holdings, Doordash, Vertex Pharmaceuticals (Aug. 5)

CORRECTED-U.S. RESEARCH ROUNDUP-Booking Holdings, Doordash, Vertex Pharmaceuticals (Aug. 5) Corrects U.S. research roundup dated Aug. 5 to remove dated research actions from headline and tables, the errors appeared in previous versions also Aug 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Booking Holdings, Doordash and Vertex Pharmaceuticals, on Monday.
A
A
B
I
M
P
A
A
E
A
E
I
A
A
A
A
F
G
H
L
L

Ecolab misses second-quarter sales estimates, shares slump

Ecolab misses second-quarter sales estimates, shares slump July 30 (Reuters) - Ecolab ECL.N reported second-quarter sales on Tuesday that missed analysts' estimates, sending the water solutions company's shares down nearly 8%. The negative stock reaction is a combination of lower-than-expected quarterly sales and investors' more ambitious earnings growth expectations in the context of more lofty valuation metrics, Vertical Research Partners analyst Kevin McCarthy said.
E

Ecolab Q2 Adjusted EPS USD 1.68 Vs. IBES Estimate USD 1.67

BRIEF-Ecolab Q2 Adjusted EPS USD 1.68 Vs. IBES Estimate USD 1.67 Jul 30 (Reuters) - Ecolab Q2 net income USD 490.9 million. Q2 sales USD 3,985.8 million vs. IBES estimate USD 4,028 million Q2 operating income USD 656.9 million Q2 EPS USD 1.71 outlook FY adjusted EPS USD 6.5-6.7 outlook Q3 adjusted EPS USD 1.75-1.85
E

Microsoft and job openings to hit pre-Fed vigil

MORNING BID AMERICAS-Microsoft and job openings to hit pre-Fed vigil A look at the day ahead in U.S. and global markets from Mike Dolan To the extent that worries about pricey tech stocks and rising AI capex spending were partly behind last week's market shakeout, Microsoft's quarterly update should prove a key moment later on Tuesday, just as the Federal Reserve's latest policy meeting gets under way.
A
A
E
G
I
M
M
N
P
S
U
A
G
J
U
U
U
F
E
E
S
A
H
L

What to Watch in the Day Ahead - Tuesday, July 30

What to Watch in the Day Ahead - Tuesday, July 30 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Microsoft is expected to report a rise in fourth-quarter revenue on robust demand for its AI-powered cloud and business software offerings.
M
M
M
P
Q
S
S
E
E
L

Ecolab Inc <ECL.N> expected to post earnings of $1.67 a share - Earnings Preview

Ecolab Inc expected to post earnings of $1.67 a share - Earnings Preview Ecolab Inc ECL.N , ECL is expected to show a rise in quarterly revenue when it reports results on July 30 for the period ending June 30 2024 The Saint Paul Minnesota-based company is expected to report a 4.6% increase in revenue to $4.028 billion from $3.85 billion a year ago, according to the mean estimate from 18 analysts, based on LSEG data.
E

U.S. Chemed, PTC Therapeutics, Regeneron Pharmaceuticals

U.S. RESEARCH ROUNDUP- Chemed, PTC Therapeutics, Regeneron Pharmaceuticals May 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Chemed, PTC Therapeutics and Regeneron Pharmaceuticals, on Tuesday. HIGHLIGHTS * Chemed Corp CHE.N : RBC cuts target price to $697 from $712 * Deckers Brands DECK.N : Barclays cuts target price to $1,026 from $1,110 * PTC Therapeutics Inc PTCT.O : Raymond James raises to market perform fro
E
I
J
N
R
D
E
A
K

U.S. AN2 Therapeutics, Ecolab, RPM International

U.S. RESEARCH ROUNDUP-AN2 Therapeutics, Ecolab, RPM International May 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AN2 Therapeutics, Ecolab and RPM International, on Thursday. HIGHLIGHTS * AN2 Therapeutics Inc ANTX.O : Evercore ISI cuts target price to $2 from $7 * Biolife Solutions Inc BLFS.O : Maxim Group raises target price to $30 from $25 * Ecolab Inc ECL.N : Evercore ISI raises target price to $250 from $1
C
A
D
E
A
C
E



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.